GoldenGolden
Advanced Search
Korro Bio

Korro Bio

Korro Bio is a company that is pioneering RNA editing to deliver the future of medicine.

Korro Bio is a company that is pioneering RNA editing to deliver the future of medicine. The company's proprietary platform, OPERA (Oligonucleotide Promoted Editing of RNA), harnesses the natural base editing system of the body, specifically ADAR (Adenosine Deaminase Acting on RNA), to make precise, single-base edits to RNA. Korro Bio was launched to turn scientific insights into life-altering new treatments for patients.

Its platform, OPERA, has been designed to address several challenges that are facing current gene therapy and gene editing approaches, including safety and flexibility of delivery mechanisms.

Korro Bio is prioritizing therapeutic indications across tissues where safe and targeted editing of messenger RNA could provide unique benefits over other modalities in development.

Timeline

May 11, 2021
Korro Bio announces the appointment of Vineet Agarwal as Chief Financial Officer.
September 2020
Korro Bio raises a $91,500,000 series A round.
September 2020
Korro Bio raises a $91,500,000 series A round.
September 2020
Korro Bio raises a $91,500,000 series A round.
September 2020
Korro Bio raises a $91,500,000 series A round.
September 2020
Korro Bio raises a $91,500,000 series A round from Alexandria Venture Investments, Atlas Venture, Cormorant Asset Management, MP Healthcare Venture Management, New Enterprise Associates, Qiming Venture Partners, Surveyor Capital and Wu Capital.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 11, 2021
BioSpace
Korro Bio, Inc ., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Vineet Agarwal as Chief Financial Officer.
Amirah Al Idrus
November 11, 2020
FierceBiotech
Fresh off a $91.5 million round, RNA-editing biotech Korro Bio has a new CEO. Ram Aiyar, Ph.D. comes on board after engineering the $2.1 billion acquisition of his previous company, Corvidia Therapeutics, by Novo Nordisk.
BioSpace
November 10, 2020
BioSpace
Korro Bio, Inc. , a biotechnology company developing single-base RNA editing therapies, today announced the appointment of Ram Aiyar, Ph.D., MBA, as its chief executive officer. Dr. Aiyar brings nearly 20 years of diverse experience across company-building, biotech and pharma to advance

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.